We do have memoranda of understanding with countries such as the United States and the European medicine evaluation agencies, as well as with Australia, Singapore, and Swissmedic. So we do have these types of collaborations; whenever there are emerging safety issues, we can contact them and share information. That's already in place.
It's also interesting to know that the whole life cycle approach, or post-market surveillance, is moving towards what we call risk management planning and pharmacovigilance planning, which is basically a way to gather information in a systematic manner once the drug is on the market. That gathering of information might occur in Canada or it might occur in other jurisdictions, but it will be reported to us by the manufacturers, so we will have access with the life cycle approach to more than what we usually and mostly relied on in the past, which was spontaneous adverse drug reaction, and we will have access to post-market safety studies that the manufacturers with a life cycle approach will now commit to in order to better monitor their products once they are on the market.
This approach is being developed internationally. The FDA and the European agencies are moving to basically develop tools that can support or complement the spontaneous adverse drug reaction systems currently in place in most countries.